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Abstract

BACKGROUND: The National Institute on Aging and
Alzheimer’s Association (NIA-AA) have proposed a new
Research Framework: Towards a biological definition of
Alzheimer’s disease, which uses a three-biomarker construct:
Aß-amyloid, tau and neurodegeneration AT(N), to generate a
biomarker based definition of Alzheimer’s disease.
OBJECTIVES: To stratify AIBL participants using the new
NIA-AA Research Framework using cerebrospinal fluid (CSF)
biomarkers. To evaluate the clinical and cognitive profiles of
the different groups resultant from the AT(N) stratification.
To compare the findings to those that result from stratification
using two-biomarker construct criteria (AT and/or A(N)).
DESIGN: Individuals were classified as being positive or
negative for each of the A, T, and (N) categories and then
assigned to the appropriate AT(N) combinatorial group: A-T(N)-; A+T-(N)-; A+T+(N)-; A+T-(N)+; A+T+(N)+; A-T+(N)-;
A-T-(N)+; A-T+(N)+. In line with the NIA-AA research
framework, these eight AT(N) groups were then collapsed
into four main groups of interest (normal AD biomarkers, AD
pathologic change, AD and non-AD pathologic change) and
the respective clinical and cognitive trajectories over 4.5 years
for each group were assessed. In two sensitivity analyses the
methods were replicated after assigning individuals to four
groups based on being positive or negative for AT biomarkers
as well as A(N) biomarkers.
SETTING: Two study centers in Melbourne (Victoria) and Perth
(Western Australia), Australia recruited MCI individuals and
individuals with AD from primary care physicians or tertiary
memory disorder clinics. Cognitively healthy, elderly NCs were
recruited through advertisement or via spouses of participants
in the study.
PARTICIPANTS: One-hundred and forty NC, 33 MCI
participants, and 27 participants with AD from the AIBL study
who had undergone CSF evaluation using Elecsys® assays.
INTERVENTION (if any): Not applicable.
MEASUREMENTS: Three CSF biomarkers, namely amyloid
β1-42, phosphorylated tau181, and total tau, were measured
to provide the AT(N) classifications. Clinical and cognitive
trajectories were evaluated using the AIBL Preclinical
Alzheimer Cognitive Composite (AIBL-PACC), a verbal
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episodic memory composite, an executive function composite,
California Verbal Learning Test – Second Edition; Long-Delay
Free Recall, Mini-Mental State Examination, and Clinical
Dementia Rating Sum of Boxes scores.
RESULTS: Thirty-eight percent of the elderly NCs had no
evidence of abnormal AD biomarkers, whereas 33% had
biomarker levels consistent with AD or AD pathologic change,
and 29% had evidence of non-AD biomarker change. Among
NC participants, those with biomarker evidence of AD
pathology tended to perform worse on cognitive outcome
assessments than other biomarker groups. Approximately
three in four participants with MCI or AD had biomarker levels
consistent with the research framework’s definition of AD or
AD pathologic change. For MCI participants, a decrease in
AIBL-PACC scores was observed with increasing abnormal
biomarkers; and increased abnormal biomarkers were also
associated with increased rates of decline across some cognitive
measures.
CONCLUSIONS: Increasing biomarker abnormality appears
to be associated with worse cognitive trajectories. The
implementation of biomarker classifications could help better
characterize prognosis in clinical practice and identify those
at-risk individuals more likely to clinically progress, for their
inclusion in future therapeutic trials.
Key words: Alzheimer’s disease, biomarkers, progression, longitudinal.

A

lzheimer’s disease (AD) is a progressive,
neurodegenerative disease characterized by
neurodegeneration, synaptic loss, and the
accumulation of extracellular-amyloid plaques and tau
intracellular neurofibrillary tangles (1, 2). Several key
imaging and cerebrospinal fluid (CSF) biomarkers have
been identified in AD (3, 4). Deposition of beta-amyloid
(Aβ-amyloid) plaques is one of the most important
pathologic hallmarks of AD and is widely thought to
be the initiating and primary driver of disease (amyloid
hypothesis) (5, 6). Measures of Aβ-amyloid include

248

JPAD - Volume 6, Number 4, 2019

amyloid imaging with positron emission tomography
(PET) as well as CSF Aβ1-42, and studies have shown
that these markers may be detectable over a decade
before symptom onset (6, 7). Neurodegeneration and
synaptic loss are also apparent prior to symptom onset,
and may be visible on brain magnetic resonance imaging
(MRI) as structural atrophy in regions consistent with
AD (3). Other methods of assessing neurodegeneration
include fluorodeoxyglucose [FDG]-PET, which measures
brain metabolism as an indicator of synaptic activity
(8, 9) and CSF total tau (t-tau), which is also indicative
of synaptic loss and neurodegeneration (4, 10). Finally,
tau pathology may be assessed using tau PET or CSF
phosphorylated tau (p-tau), which has shown utility for
predicting progression from mild cognitive impairment
(MCI) to AD dementia as well as differentiating AD from
other forms of dementia (3, 4, 11, 12).
Based on these biomarkers of Aβ-amyloid (CSF Aβ1–
42), neurodegeneration (t-tau) and tau pathology (p-tau),
various constructs have been developed to accurately
identify individuals in the earliest (pre-symptomatic)
stages of disease who are likely to progress to MCI and
AD. Initial diagnostic research criteria developed by the
National Institute on Aging and Alzheimer’s Association
(NIA-AA) classified individuals with evidence of
Aβ-amyloid pathology (i.e., abnormal Aβ-amyloid PET
and CSF Aβ-amyloid) into three stages of preclinical AD
based on the presence or absence of markers of neuronal
injury (i.e., FDG-PET, structural MRI, or measures of
tau) and evidence of subtle cognitive change (13). The
criteria were further expanded to include two additional
categories for cognitively normal individuals, including
those with no biomarkers of AD (i.e., normal Aβ-amyloid,
neurodegeneration, and tau) and those without evidence
of Aβ-amyloid pathology but who are positive for
other markers of neuronal injury, also referred to as
suspected non-AD pathophysiology (SNAP) (14).
These classifications were able to characterize 97% of
cognitively normal individuals from a populationbased sample (14) and have been shown to correlate
with the cognitive trajectories and disease progression of
individuals over time (15, 16).
While previous iterations of the NIA-AA criteria
were based on a two-marker construct using evidence
of Aβ-amyloid pathology and neurodegeneration as a
single category, it is thought that segregating measures
of pathologic tau (i.e., tau PET, CSF p-tau) from other
markers of neuronal injury may help to better distinguish
AD-related pathology from other neurodegenerative
conditions (3). The recent NIA-AA Research Framework:
Towards a biological definition of Alzheimer’s disease
(4) is therefore based on a three-marker construct. The
recent framework uses normal (-) or abnormal (+) levels
of Aβ-amyloid deposition (“A”), pathologic tau (“T”),
and neurodegeneration (“(N)”) as constructs to create
the AT(N) classification system. In this contribution, we
interrogated the AT(N) classification system to improve

understanding for its implementation and applicability
in characterizing and understanding the pathogenesis
of AD. Firstly, we apply the AT(N) classification system
to CSF biomarkers from well-characterized participants
in the longitudinal Australian Imaging, Biomarker &
Lifestyle (AIBL) Flagship Study of Ageing. Secondly, we
describe the long-term clinical and cognitive trajectories
of AIBL elderly cognitively normal controls (NCs) as
well as AIBL MCI individuals, using the three-marker
construct.

Methods
The AIBL cohort
The AIBL cohort study of aging combines data
from neuroimaging, biomarkers, lifestyle, clinical, and
neuropsychological assessments. Two study centers in
Melbourne (Victoria) and Perth (Western Australia),
Australia recruited individuals with MCI and with
AD from primary care physicians or tertiary memory
disorders clinics. Cognitively healthy NC participants
were recruited through advertisement or via spouses
of participants in the study. Exclusion criteria included
a history of non-AD dementia, Parkinson’s disease,
schizophrenia, bipolar disorder, current depression,
cancer in the past 2 years (with the exception of basalcell skin carcinoma), symptomatic stroke, uncontrolled
diabetes, or current regular alcohol use. Between
November 3, 2006, and October 30, 2008, AIBL recruited
1112 eligible volunteers who were at least 60 years old
and fluent in English. Full details on the study design
and inclusion criteria have been reported elsewhere
(17). An enrichment cohort of 86 participants with AD,
124 MCI participants, and 389 NC participants were
recruited by AIBL between March 30, 2011, and June 29,
2015. At baseline, the AIBL study participants had an
average age of 72 years, 58% were female, and 36% were
Apolipoprotein E (APOE) ε4 carriers. APOE ε4 carriage
was determined as previously described (18). Two
hundred AIBL participants (140 NC, 33 MCI and 27 AD)
with a mean age of 73 (50% Males) who had undergone
lumbar puncture were included in the current study.

Assessment of CSF biomarkers
Lumbar puncture was used to collect CSF from 200
AIBL participants in the morning after overnight fasting,
with a protocol aligned to the Alzheimer’s Biomarkers
Standardization Initiative (ABSI). Lumbar puncture was
performed in the sitting position using a strictly aseptic
technique and gravity drip collection. CSF was collected
into a polypropylene tube and placed on ice prior to
centrifugation (2000 ×g at 4°C for 10 minutes), and the
supernatant was transferred to a second polypropylene
tube and gently inverted. Samples were aliquoted
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(500 μL) into Nunc cryobank polypropylene tubes
(NUN374088) and stored in liquid nitrogen vapor tanks
within 1 hour (kept on dry ice prior to storage) and
only thawed once, immediately before analysis. CSF
levels of Aβ1-42, t-tau, and p-tau were measured by
electrochemiluminescence Elecsys® immunoassay (Roche
Diagnostics, Penzberg, Germany) that uses a quantitative
sandwich principle. Levels were measured using the
Roche cobas® e601 analyzer (Roche Diagnostics) with a
total assay duration of 18 minutes.

Application of the NIA-AA Research
Framework
The NIA-AA Research Framework (4), details
grouping of individuals based on AT(N) criteria,
where: ‘A’ represents Aβ-amyloid or associated
pathologic state—here ‘A’ is defined using CSF Aβ142; ‘T’ represents aggregated tau (neurofibrillary
tangles) or associated pathologic state—in this current
study ‘T’ is defined using CSF p-tau; ‘(N)’ represents
neurodegeneration or neuronal injury—here ‘(N)’
is defined using CSF t-tau. Individuals were classified
as being positive or negative for each of the A, T, and
(N) criteria. A+ was defined as having a CSF Aβ1-42
level ≤1054.00pg/mL and A- as having a CSF Aβ1-42
level >1054.00 pg/mL. T+ was defined as having a CSF
p-tau level ≥21.34 pg/mL and T- as having a CSF p-tau
level <21.34 pg/mL. (N)+ was defined as having a CSF
t-tau level ≥212.60 pg/mL and T- as having a CSF p-tau
level <212.60 pg/mL. Individuals were then classified
as belonging to one of the eight AT(N) combinatorial
groups: A-T-(N)-; A+T-(N)-; A+T+(N)-; A+T-(N)+;
A+T+(N)+; A-T+(N)-; A-T-(N)+; A-T+(N)+. In line with
the NIA-AA Research Framework (4), the eight AT(N)
groups were collapsed into four main groups of interest:
those with normal AD biomarkers (A-T-(N)-), those
with non-AD pathologic change (A-T+(N)-; A-T+(N)+;
A-T+(N)-), those with AD pathologic change (A+T-(N)-;
A+T-(N)+), and those with AD (A+T+(N)-; A+T+(N)+).

Cognitive markers
All participants underwent extensive
neuropsychological testing, as previously described
(17). Briefly, the tests comprising the AIBL clinical and
neuropsychological battery were selected to cover the
main domains of cognition affected by AD and other
dementias, and are all internationally recognized as
having good reliability and validity. The full battery
comprised: the Clinical Dementia Rating (CDR) Scale,
Mini-Mental State Examination (MMSE) (19), ClockDrawing Test, California Verbal Learning Test – Second
Edition (CVLT-II) (20), Logical Memory (LM) I and II
(Wechsler Memory Scale [WMS]-III; Story A only) (21-23),
Delis–Kaplan Executive Function System (D-KEFS) verbal

fluency (24), 30-item Boston Naming Test (BNT) (25),
the Stroop Test (Victoria version) (22), the Rey Complex
Figure Test (RCFT) (26), Digit Span and Digit SymbolCoding subtests of the Wechsler Adult Intelligence Scale
– Third Edition (WAIS–III) (27), the Wechsler Test of
Adult Reading (WTAR) (28), the Hospital Anxiety and
Depression Scale (HADS), and the Geriatric Depression
Scale (GDS).
Clinical and cognitive trajectories were evaluated using
the AIBL-Preclinical Alzheimer Cognitive Composite
(AIBL-PACC) (29), a verbal episodic memory composite,
an executive function composite (30), CVLT-II LongDelay Free Recall (CVLT-II LDFR), MMSE, and CDR
Sum of Boxes (CDR SoB) measures. The AIBL-PACC was
constructed by summing Z-score measures of CVLTII LDFR, LM-II, MMSE, and Digit Symbol-Coding.
The verbal episodic memory composite was created
from Z-scores of CVLT-II LDFR, CVLT-II recognition
false positives, and LM-II, and the executive function
composite was generated from Z-scores of D-KEFS letter
fluency and category switching totals as well as the
colors/dots interference measure from the Stroop Test
(Victoria version).

Analysis
Demographic information was assessed across
clinical classifications for 200 AIBL participants who had
undergone CSF evaluation. Participants were classified
into one of eight categories based on the three-construct
model of AT(N) in the NIA-AA Research Framework.
The prevalence of the AT(N) groups was assessed across
the clinical classification groups. The eight AT(N) groups
were then collapsed into four main groups of interest:
those with normal AD biomarkers, those with non-AD
pathologic change, those with AD pathologic change,
and those with AD. Baseline cognitive performance was
assessed across these four groups within the NC and MCI
clinical classification groups using boxplots and one-way
t-tests. Longitudinal change in cognitive performance
over time, separately for the NC and MCI, was assessed
using boxplots and one-way t-tests of the random slopes
obtained from linear mixed-effect models. In the linear
mixed-effect models, the cognitive measure represented
the dependent variable; age, sex, and APOE ε4 status
were included as interacting independent factors and
time since CSF evaluation was included as a random
factor. The dependent variable was evaluated every 18
months for a mean follow-up of 4.5 years. The number of
participants progressing towards more advanced disease
(i.e., NC to MCI/AD and MCI to AD) within each of
these four groups was also evaluated using descriptive
statistics, due to the small number of conversions more
sophisticated analyses such as Cox proportional hazards
analyses could not be undertaken.
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Table 1. Demographics
Metric

AD

MCI

NC

Total

Number of participants

27

33

140

200

Males, n (%)

15 (55.6)

23 (69.7)

61 (43.6)

99 (49.5)

Mean age, years (SD)

73.77 (8.2)

73.1 (6.5)

72.15 (6.0)

72.54 (6.3)

<9

4 (16.7)

5 (15.2)

6 (4.3)

15 (7.6)

9-12

10 (41.7)

15 (45.5)

53 (37.9)

78 (39.6)

13-15

5 (20.8)

5 (15.2)

25 (17.9)

35 (17.8)

>15

5 (20.8)

8 (24.2)

56 (40.0)

69 (35.0)

APOE ε4 carriers, n (%)

12 (44.4)

11 (33.3)

31 (22.1)

54 (27)

Mean duration of follow-up, years (SD)

2.78 (2.0)

3.56 (2.3)

5.14 (2.7)

4.54 (2.7)

Years of education, n (%)

AD, Alzheimer’s disease; APOE, Apolipoprotein E; MCI, mild cognitive impairment; NC, normal control; SD, standard deviation.

Sensitivity Analysis I
Participants were assigned to one of four groups (A-T-;
A+T-; A-T+; A+T+) based on their CSF Aβ1-42 and p-tau
levels as described above. Baseline cognitive performance
was assessed across these four AT groups within each
clinical classification group using boxplots and one-way
t-tests. Longitudinal change in cognitive performance
over time was assessed using boxplots and one-way
t-tests of the random slopes obtained from linear mixedeffect models. In the linear mixed-effect models, the
cognitive measure represented the dependent variable;
age, sex, and APOE ε4 status were included as interacting
independent factors and time since CSF evaluation was
included as a random factor.

(n=33 and n=27, respectively) (Table 1). There was a
higher prevalence of males in the MCI and AD samples
compared to the NC sample. Reported ages at baseline
did not differ across the three samples (averaging around
73 years). The NC participants had a higher level of
education and had fewer APOE ε4 carriers. The mean
duration of follow-up for all participants was 4.54 years.
Figure 1. Prevalence of the AT(N) groups across clinical
classifications

Sensitivity Analysis II
Participants were assigned to one of four groups
(A-N-; A+N-; A-N+; A+N+) based on their CSF Aβ1-42
and t-tau levels as described above. Baseline cognitive
performance was assessed across these four A(N) groups
within each clinical classification group using boxplots
and one-way t-tests. Longitudinal change in cognitive
performance over time was assessed using boxplots and
one-way t-tests of the random slopes obtained from
linear mixed-effect models. In the linear mixed-effect
models, the cognitive measure represented the dependent
variable; age, sex, and APOE ε4 status were included
as interacting independent factors and time since CSF
evaluation was included as a random factor.

Results
AD, Alzheimer’s disease; MCI, mild cognitive impairment

Demographics
The majority of participants (140/200) were cognitively
healthy (NC) and the remaining comprised MCI or AD
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Figure 2. Cross-sectional performance on the six cognitive measures (A: AIBL-PACC; B: Verbal Episodic Memory; C:
Executive Function; D: CDR Sum of Boxes; E: MMSE; F: CVLT-II LDFR) for the four contracted AT(N) groups in NC

AD, Alzheimer’s disease; AIBL-PACC, Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing – Preclinical Alzheimer Cognitive Composite; CDR, Clinical
Dementia Rating; CVLT-II LDFR, California Verbal Learning Test – Second Edition; Long-Delay Free Recall; MMSE, Mini-Mental State Examination; NC, normal control;
SD, standard deviation.

Prevalence of AT(N) groups
The prevalence of each of the eight AT(N) classifications
within the AIBL NC, MCI, and AD samples are given in
Figure 1. The highest proportion of NC participants (38%)
had normal AD biomarkers; 13% had AD pathologic
change, 20% have AD, and 29% had non-AD pathologic
change. In the MCI and AD samples, 75% and 70% of
participants had AD pathologic change, respectively.

Cross-sectional cognitive performance in NC
In general, NC participants with biomarkers consistent
with AD performed the worst on the cognitive composite
markers and MMSE (Figure 2A‒C and E). Differences
were not observed for CDR SoB with all NCs scoring 0
on this test (Figure 2D). The NC participants with normal
AD biomarkers had the lowest scores on the CVLT-II
LDFR (Figure 2F). In general, within the NC sample
those classified as having non-AD pathologic change
had similar scores to those with normal AD biomarkers.
Regarding the sensitivity analyses, The A+T+ group had
significantly (p=0.03) lower baseline scores for AIBLPACC in comparison to the A-T- group and the A+T+
group had significantly lower baseline scores for the
Verbal Episodic Memory composite than the A-T+ group.

Also, the A+N+ group had significantly lower baseline
scores for the Verbal Episodic Memory composite than
the A-N+ group. No other differences were observed
in the sensitivity analyses of differences in the NC at
baseline.

Cross-sectional cognitive performance in MCI
For MCI participants there was a decrease in
performance from those with normal AD biomarkers, to
those with AD pathologic change and then AD for the
AIBL-PACC (Figure 3A). This trend was not observed in
the other five clinical and cognitive markers considered
(Figure 3B–F). No baseline differences were obsevered for
the MCI in the sensitivity analyses.

Longitudinal change in cognitive performance
For both the NC and MCI participants, systematic
differences were not observed in the rates of decline for
the four groups considered (Supplementary Figures 1
and 2). No differences were observed in the sensitivity
analyses.
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Figure 3. Cross-sectional performance on the six cognitive measures (A: AIBL-PACC; B: Verbal Episodic Memory; C:
Executive Function; D: CDR Sum of Boxes; E: MMSE; F: CVLT-II LDFR) for the four contracted AT(N) groups in MCI

AD, Alzheimer’s disease; AIBL-PACC, Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing – Preclinical Alzheimer Cognitive Composite; CDR, Clinical
Dementia Rating; CVLT-II LDFR, California Verbal Learning Test – Second Edition; Long-Delay Free Recall; MMSE, Mini-Mental State Examination; MCI, mild cognitive
impairment; SD, standard deviation.

Progression to disease
Over the period of follow-up (mean=4.54 years), of
the 53 NC individuals with normal AD biomarkers, one
progressed to MCI due to AD and one progressed to
MCI not due to AD. Of the 18 NC individuals with
AD pathologic change, two progressed to MCI due to
AD. Of the 28 NC individuals with AD biomarkers, one
participant died and there were no other transitions.
Of the 41 individuals with non-AD pathologic change,
one participant died, one progressed to MCI, and one
progressed to vascular dementia. Of the nine MCI
individuals with AD pathologic change, one progressed
to AD. Of the 13 MCI individuals with AD biomarkers,
two participants died and two progressed to AD. There
were not enough events of progression to ascertain any
statistically significant differences in progression between
the groups.

Discussion
This analysis evaluated the AT(N) classification system
in a well-characterized population from the AIBL cohort,
including cognitively healthy NC participants as well
as those with MCI and AD. Approximately two in five
of the elderly NC had no evidence of abnormal AD

biomarkers, whereas one in three had biomarker levels
consistent with AD or AD pathological change and
almost one in three had evidence of non-AD pathological
change. Twenty-three percent of the NC participants
had biomarker levels aligned with the SNAP category
(A-(N+)), which aligns with other reports in the literature
(3, 16).
Among NC participants, those with biomarker
evidence of AD pathology tended to perform worse on
composite cognitive outcome assessments and the MMSE
compared with other biomarker groups. Participants
with abnormal non-AD-specific biomarkers performed
similarly to those with or without normal AD biomarkers
across endpoints. No differences were observed across
the four biomarker groups with respect to rate of decline
on any outcome assessment.
Approximately three in four participants with MCI
or AD had biomarker levels consistent with AD or AD
pathologic change. For MCI participants, a decrease
in AIBL-PACC scores was observed with increasing
abnormal biomarkers; increased abnormal biomarkers
were also associated with increased rates of decline across
some cognitive measures. There were not enough events
of disease progression (i.e., NC to MCI/AD or MCI to
AD) to draw any conclusions about the risk of disease
progression based on the biomarker constructs.
Despite the lack of statistically significant trends,
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which is likely to be related to the small numbers of
participants included, observations from the current
study are qualitatively consistent with previous work
showing that biomarkers of AD evident before clinical
symptoms appear to predict cognitive deficit. In a natural
history study classifying NC participants (N=166) with a
two-marker construct, using Aβ-amyloid (assessed using
amyloid PET imaging) and markers of neurodegeneration
(hippocampus volume seen on MRI, FDG-PET), those
with normal AD biomarkers showed improvement over
time on a composite cognitive measure derived from
eight neuropsychological tests, likely due to practice
effects (15). Conversely, participants who either had
evidence of Aβ-amyloid pathology or were considered
SNAP participants had reduced practice effects, and
those positive for both Aβ-amyloid pathology and
markers of neurodegeneration showed cognitive decline
(15). An analysis of a larger group of NC individuals from
the AIBL cohort (N=573) also applied the two-marker
construct, using amyloid PET as a marker of Aβ-amyloid
pathology and hippocampal volume on MRI to assess
neurodegeneration, and showed that amyloid-PET
positivity conferred significant risk for cognitive decline,
with structural evidence of neurodegeneration further
compounding this risk (16). Applying this two-marker
construct here in a sensitivity analysis, highlighted
some baseline differences: individuals with abnormal
CSF levels for Aβ-amyloid and one of the tau markers
performed worse than participants with less biomarker
abnormality on two of the cognition measures. No
longitudinal differences were observed in the sensitivity
analysis.
The composite AT(N) system for classifying AD
used in the present analysis separates markers of tau
pathology from other neurodegenerative markers
which is thought to improve specificity in terms of
differentiating patients with AD vs. non-AD pathology.
However, our inconclusive findings suggest that
further study of the AT(N) classification system and its
comparison to the two-biomarker constructs in larger
groups of participants across the disease spectrum is
needed.
Our construct employed CSF-based immunoassay
measures for determining A, T, and (N) status, in
comparison to the imaging metrics employed in the
previous studies discussed (15, 16). The availability
of immunoassay methodology for evaluating AD and
neurodegeneration biomarkers could have important
implications for clinical practice as this type of testing
may be more widely accessible and cheaper than
imaging-based methodologies. In turn, this potential
for great accessibility vs. imaging methodologies may
facilitate wider application of AT(N) classification in
clinical trial methodology to screen more potential
participants and further enrich study populations with
AD biomarker-positive individuals who are most likely
to show AD-related disease progression within the

duration of the study. A much wider application would
be achievable once blood biomarkers become available.
There are a number of limitations to this study,
including the small sample size, which may preclude
any statistically significant differences being observed.
Further, only a small number of disease progression
events occurred precluding any evaluations to be made
regarding the power of the AT(N) criteria to predict
progression to disease. The participants were volunteers
who were not randomly selected from the community,
and were generally well educated; thus, these findings
might only be valid in similar cohorts and this limitation
precludes the generalization of the findings. In view
of the stringent selection criteria in AIBL, which
excluded individuals with cerebrovascular disease or
other dementias, the effect of other comorbidities on
the trajectories might be underestimated. Longitudinal
cognitive performance was based on three composite
measures as well as two clinical scores and one standard
measure, which were corrected using within-study
norms; however, other cognitive tests, or combinations
thereof, might yield different results. Further, biomarker
levels were obtained from a CSF immunoassay and
different techniques may yield different results. The cutoffs used for dichotomous stratification were somewhat
arbitrary and continuous variables might provide better
predictors of progression. Another potential limitation is
the non-specificity of t-tau for the (N) classification and
other markers, such as neurofilament light, either in CSF
of plasma, may provide a more robust assessment of (N).
In conclusion, increasing CSF biomarker abnormality
appears to be associated with worse cognitive trajectories.
The implementation of the AT(N) classification could
help better characterize prognosis in clinical practice and
identify those at-risk individuals more likely to progress,
for inclusion in future therapeutic trials. However,
our inconclusive findings suggest that further study
of the AT(N) classification system in larger groups of
participants is warranted.
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